Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort | Zendy

Marine Perrier | Zendy; Charlotte Charpentier | Zendy; Gilles Peytavin | Zendy; Minh Patrick Lê | Zendy; Louis Blondel | Zendy; Benoît Visseaux | Zendy; Véronique Joly | Zendy; A. Pinto | Zendy; Sophie Matheron | Zendy; Yazdan Yazdanpanah | Zendy; Diane Descamps | Zendy; Roland Landman | Zendy

Open Access

Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort

Author(s) -

Marine Perrier,

Charlotte Charpentier,

Gilles Peytavin,

Minh Patrick Lê,

Louis Blondel,

Benoît Visseaux,

Véronique Joly,

A. Pinto,

Sophie Matheron,

Yazdan Yazdanpanah,

Diane Descamps,

Roland Landman

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx018

Subject(s) - elvitegravir , cobicistat , medicine , viral load , emtricitabine , cohort , regimen , integrase inhibitor , pharmacology , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as a single-tablet regimen (STR) using the PCR signal of the plasma viral load (pVL) assay and determination of plasma drug concentration ( C 24 ).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research